

## Moving Beyond Big Data and AI to Realize the Dream of Precision Medicine

January 23, 2020

# Sema4: A patient-centered health intelligence company

Use data analytics to develop **predictive models** of human health

Q

Define optimal individualized health course trajectories to improve patient outcomes.



Deliver information-driven insights to pharma/biotech companies to **accelerate drug development** of precision medicines.

## Sema4: Patient-centered predictive health company

- Spun out of Mount Sinai, a premier research and patient care organization and one of largest healthcare systems in US, in 2017
- Interdisciplinary team of scientists, data engineers, and clinicians, transforming future of healthcare through data-driven insights (~850 Employees; ~150 PhD/MD level scientists)
- One of largest clinical genomics labs in the world
  - >150,000 advanced DNA tests run/year
  - Test volume more than doubling yearly
- Founded on idea that more information, deeper analysis, and increased engagement will improve diagnosis, treatment, and prevention of disease



semo

Healthcare decisions are binary, ignoring that every individual is unique and therefore requires unique healthcare recommendations



With increasing amounts of data from advanced technologies generated on patients, we can do better



Our AI-driven models make maximal use of individual patient data, in the context of the digital universe of data to enable more informed and accurate decisions

## Rapid technology advances $\rightarrow$ massive scales of data informing on individuals



Mobile + Social Networks



The Cloud



**Big Data Analytics** 

Only technology I am aware of that is moving at super Moore's law speed





FUR YOUR EYES ONLY CIA 'implanted microphones into CATS' in a bizarre attempt to spy on Russia



**Advanced Materials** 



**3D Printing** 



The "Internet of Things"



What does it mean to move at Super Moore's Law pace? Well consider moving at a Moore's Law pace...

Technologies like NGS have led to enough new knowledge in the past decade that everyone would benefit from sequencing today



## Sema4 conducts advanced genetic testing during key stages in patients' lives

Focus of these materials Pre-pregnancy & Pregnancy\* **Pediatric** Adult/Oncology **Carrier Screening: Hereditary Cancer:** Natalis: Enhanced reports Supplemental newborn screening Multigene panels across cancer types ٠ Personalized residual risk Molecular Oncology: Diagnostic panels: Solid Tumor and Heme Onc NIPT: Hearing and vision loss . Targeted and expansive screening Cardiac defects Somatic and Germline profiling • **Prenatal:** Primary immunodeficiency/IBD Whole transcriptome profiling . • Neurodevelopmental panels including Diagnosis for high risk pregnancies **Comprehensive Pan-cancer** • • • Noonan syndrome and ASD Cytogenomic analysis Pharmacogenomic Panels IVF: Skeletal dysplasias/Limb defects **Genomic Health Screening** . Reference agreement for PGT-A and Microcephaly . PGT-M **Diagnostic Exome** . Expanded Carrier Screening (> 500 Genes) Hereditary Cancer (>100 Genes) Solid/Liquid Tumors (Whole Exome/Transcriptome) Our Expanded Carrier Screen provides insight into Genetic testing for hereditary cancer can help Designed to help identify appropriate targeted determine if a patient carries a genetic change therapies and clinical trials for patients with solid carrier status to help patients make informed family planning choices that increases their risk for certain cancers tumors Conditions covered span: cardiovascular, endocrine, 20+ genes found in 115+ genes included in 15t genes associated with Testing panels analyze genes associated with 800+ clinical trials 30+ targeted therapies hematologic, hepatic, immunodeficiency, brain, breast, colon, melanoma, ovarian, 15+ guidelines metabolic, neurological, pulmonary, renal, and pancreatic, and prostate cancers for solid tumor genetic testing worldwide that are approved by the FDA skeletal conditions \*Majority of testing volume; additional detail on reproductive health tests on following slide

## Convenient At Home Genetic Testing, Education & Support







In areas like cancer, sophisticated data matched with sophisticated AI and machine learning approaches to inform diagnosis and treatment

> Patient tumor and germline are profiled, key drivers identified, tumor constructed in avatar models, those models taken through HTS for identification of drug cocktail



## Sema4: driving differentiated insights

#### **Track Samples**

z new abnormal results					
<ul> <li>2 new negative results</li> </ul>					
<ul> <li>2 new inconclusive re-</li> </ul>	sults				×
Orders View by	Filter by				Clear All
	Filter by Test	•	Order status	Location	Clear All
View by		•	Order status	Location	•
View by			Partner Date of Birth	Location	•
View by Recently updated • Patient Name Publish D/MRN	Test Patient Date of B 11/04/1973	ith Partner Name	Partner Date of Birth	Reat	e 1-3 of 3 Otter Date
View by Recently updated • Patient Name Reg.Jaan 75924535	Test Patient Date of B \$\$1/04/1983	ith Partner Name Summers, Scot	Partner Date of Birth 8 09/06/1982		e 1-3 of 3 Otter Date

#### **Review Results**

- Clinical trials
- Therapy , prognosis
- VUS

#### Interactive Results & Analytical Updates

- FDA approved therapies
- Clinical trials eligibility
- Relevant publications
- Practice level statistics



 Pathway driven recommendations to further personalize treatment decisions

6

#### Patient Journey & Cohort Builder

- Compare to relevant cohorts
- Review your patient files
   longitudinally



#### Place Order\*

		sema4			
lace	lace a new order				
inasa cor	rpinte all sections of this form to place an order. You	may save your draft at any time to complete the order later.			
0	Inder Information				
0	atient Information				
0	Rilling				
01	iests				
Select	a task to add it to this order.	Close all			
Prefer	red Tests				
•	atom carrier screen				
2	one indicate the diseaseful to test for Select all that apply				
	e				
	Abetalgopreterierina IMTTR	Caretoral constitue deficiency syndrome 1 53,0548			
	Advorstopsis (NG83)	Central creative deficiency syndrome 2 (SANT)			
	Acodematia enteropatrica (SLC39Ad)	Careterotandinous xonthomaticals (CVPepild			
	Acute Infertile low failure (2014,2	Churcht-Matio Tooth classes, type 42 (MDR2)			
	Acyl-CaA oxidase I deficiency UNDOCA	Charact-Mate-Taoh disease type 5 and Arts syndrome PRPS2			
	Indenesine dearninase deficiency (ADA)	Charaot, Morie Torch elsesse, 3: Indeed 62,800			
	Advendeshedgebophy; X-limited (ABCD)	Chorecacaethorytosis friP5c2N			
	Acard-Costern and one 56MRDs	Dapidearria 0.04			



## Equity in Comprehensive Testing Starts With Affordable Access

Robust In-network Payer Contracts (covering > 200 million lives in the U.S.)





Align with our patient and provider focused goals

## Support for providers

- Workflow integration
- Dedicated Customer Success Team
- Ethical billing practices
- Expansive pre-authorization services
- Digital tools to engage results easily and securely
- Proactive genetic counseling

### Support for patients

- National payor network
- Patient-friendly billing policies
- Benefits investigation service
- Digital tools keeping data secure and patients in control
- Proactive genetic counseling
- Affordable discounted or free rates for those in need